61
HYPERSENSITIVITY. HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR TRANSPLANTATION AND TUMOR IMMUNITY IMMUNITY Medical biology, microbiology, virology, immunology department By as. E.V. Pokryshko

HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

  • Upload
    sherry

  • View
    46

  • Download
    0

Embed Size (px)

DESCRIPTION

Medical biology, microbiology, virology, immunology department. HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY. By as. E.V. Pokryshko. HYPERSENSITIVITY (ALLERGY) - PowerPoint PPT Presentation

Citation preview

Page 1: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

HYPERSENSITIVITY.HYPERSENSITIVITY.

TRANSPLANTATION AND TRANSPLANTATION AND TUMOR IMMUNITYTUMOR IMMUNITY

Medical biology, microbiology, virology, immunology department

By as. E.V. Pokryshko

Page 2: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

HYPERSENSITIVITY (ALLERGY)

When an immune response results in exaggerated or inappropriate reactions harmful to the host, the term hypersensitivity, or allergy, is used. The clinical manifestations of these reactions are typical in a given individual and occur on contact with the specific antigen (allergen) to which the individual is hypersensitive.

Page 3: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

AllergensAllergens are subdivided into household and epidermal (the dust of feather quilts and pillows, skin epidermis, dandruff of dogs, cats, and horses, etc.), occupational (library dust, dust of wool and cotton, certain dyes, soaps, varnishes, wood pulp, explosives and synthetic substances, etc.), plant (the pollen of plants during pollination of meadow grasses, garden and potted plants), food (eggs, strawberries, shellfish, citrus fruits, coffee, chocolate, and other foods), drug (codeine, acetylsalicylic acid, sulphanilamides, penicillin and other antibiotics).

Page 4: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 5: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

The activity of allergens is determined by their structure and the position of the determinant groups in their molecules.

The allergens are of bacterial and fungal origin, protein-polysaccharide-lipid complexes. Different allergens have antigenic determinants in common (polyvalent character of allergic reactions).

Page 6: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Peter Gell and Robert Coombs developed a classification system for reactions responsible for hypersensitivities in 1963. Their system correlates clinical symptoms with information about immunologic events that occur during hypersensitivity reaction.

The Gell-Coombs clasification system divides hypersensitivity into four types:

Type I (Anaphylaxis) HypersensitivityType II (Cytotoxic) HypersensitivityType III (Immune Complex) HypersensitivityType IV (Cell-Mediated) Hypersensitivity

Page 7: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Allergic reactionsAllergic reactions are subdivided into two groups: 1. immediate, 2. delayed reactions.

Although it is difficult to draw a strict distinction between them. Allergic reactions of immediate action are associated with B-lymphocytes and antibodies circulating in the blood, allergic reactions of delayed action with T-lymphocytes.

Page 8: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

TYPE I: IMMEDIATE HYPERSENSITIVITYTYPE I: IMMEDIATE HYPERSENSITIVITY

(ANAPHYLACTIC)(ANAPHYLACTIC) 

An immediate hypersensitivity reaction occurs when antigen binds to IgE on the surface of mast cells with the consequent release of several mediators. The process begins when an antigen induces the formation of IgE antibody, which binds firmly by its Fc portion to basophils and mast cells. Reexposure to the same antigen results in cross-linking of the cell-bound IgE and release of pharmacologically active mediators within minutes (immediate reaction). Cyclic nucleotides and calcium play essential roles in release of the mediators.

Page 9: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

No single mediator accounts for all the manifestations of type I hypersensitivity reactions. Some important mediators and their effects are as follows:

(1) Histamine occurs in granules, of tissue mast cells and basophils in a preformed state. Its release causes vasodilation, increased capillary permeability, and smooth-muscle contraction. Clinically, disorders such as allergic rhinitis (hay fever), urticaria, and angioedema can occur. The bronchospasm so prominent in acute anaphylaxis results, in part, from histamine release.

(2) Slow-reacting substance of anaphylaxis (SRS-A) consists of several leukotrienes, which do not exist in a preformed state but are produced during anaphylactic reactions. Leukotrienes are formed from arachidonic acid by the lipoxygenase pathway and cause increased vascular permeability and smooth-muscle contraction.

Page 10: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

(3) Eosinophil chemotactic factor of anaphylaxis (ECF-A) (4) Serotonin is preformed in mast cells and blood platelets. When released during anaphylaxis, it causes capillary dilation, increased vascular permeability, and smooth-muscle contraction (5) Prostaglandins and thromboxanes are related to leukotrienes. Prostaglandins cause dilation and increased permeability of capilaries and bronchoconstriction. Thromboxanes aggregate platelets.

Page 11: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 12: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 13: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 14: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Stages of reaction Stages of reaction and mechanismand mechanism

Prevention therapyPrevention therapy

Allergen penetrates into individual

Avoid meeting allergen

IgE antibody is induced by allergen and binds to mast cells and basophils

Desensitization

When exposed to the al- lergen again, the allergen cross-links the bound IgE,which induces degra-nulation

Stabilization of mast cells (chromolyn sodium, theocine, caffeine)

Release of mediators Antagonists of mediators,

Antihistamine drugs

Local manifistations:

rhinitis, asthma, urticaria

Inhibitors of late stage.

Corticosteroides, indometacin

Page 15: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Atopy.Atopy. Atopic disorders, such as hay fever, asthma, eczema, and urticaria, are immediate-hypersensitivity reactions that exhibit a strong familial predisposition and are associated with elevated IgE levels. Several processes seem likely to play a role in atopy, for example, failure of regulation at the T cell level (eg, increased production of interleukin-4 leads to increased IgE synthesis), enhanced uptake and presentation of environmental antigens, and hyperreactivity of target tissues. It is estimated that up to 40% of people in the United Stales have experienced an atopic disorder at some time in their lives.

The symptoms of these atopic disorders are induced by exposure to the specific allergens. These antigens are typically found in the environment (eg, pollens and dust mite feces often found in bedding and carpet) or in foods (eg, shellfish and nuts).

Page 16: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 17: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Skin testing can be used for identify the allergen responsible for allergies. These tests involve inoculating small amounts of suspect allergen into the skin. Sensitivity to the allergen is shown by a rapid inflammatory reaction characterizide by redness, swelling, and itching at the site of inoculation

Page 18: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 19: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Desensitization Major manifestations of anaphylaxis occur when large amounts of mediators are suddenly released as a result of a massive dose of antigen abruptly combining with IgE on many mast cells. This is systemic anaphylaxis, which is potentially fatal. Desensitization can prevent systemic anaphylaxis.

Page 20: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

H2 blockers inhibiting allergic response. Antigens (green triangles) enter the body, bind with IgE on mast cells (middle left), and trigger the release of histamine (green balls). Histamine attaches to receptors on blood vessels, causing vasodilation, edema, and inflammation. H2 blocker drugs

(yellow balls) block histamine from engaging the receptors.

Page 21: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Acute desensitization involves the administration of very small amounts of antigen at 15-minute intervals. Antigen-IgE complexes form on a small scale, and not enough mediator is released to produce a major reaction. This permits the administration of a drug or foreign protein to a hypersensitive person, but hypersensitivity is restored days or weeks later.

Page 22: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Chronic desensitization involves the long-term weekly administration of the antigen to which the person is hypersensitive. This stimulates the production of IgG-blocking antibodies in the serum, which can prevent subsequent antigen from reaching IgE on mast cells, thus preventing a reaction.

Page 23: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 24: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 25: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

TYPE II: CYTOTOXIC HYPERSENSITIVITYTYPE II: CYTOTOXIC HYPERSENSITIVITY

Cytotoxic hypersensitivity occurs when antibody directed al antigens of the cell membrane activates complement. This generates a membrane attack complex, which damages the cell membrane. The antibody (IgG or IgM) attaches to the antigen via its Fab region and acts as a bridge to complement via its Fc region. As a result, there is complement-mediated lysis as in hemolytic anemias, ABO transfusion reactions, or Rh hemolytic disease. In addition to causing lysis, complement activation attracts phagocytes to the site, with consequent release of enzymes that damage cell membranes.

Page 26: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 27: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 28: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Drugs (eg, penicillins, phenacetin, quinidine) can attach to surface proteins on red blood cells and initiate antibody formation. Such autoimmune antibodies (IgG) then interact with the red blood cell surface and result is hemolysis.

Certain infections, eg, Mycoplasma paeumoniae infection, can induce antibodies that cross-react with red cell antigens, resulting in hemolytic anemia.

Page 29: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 30: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

In rheumatic fever, antibodies against the group A streptococci cross-react with cardiac tissue.

Other drugs can attach to platelets and induce autoantibodies that lyse the platelets, producing thrombocytopenia and, as a consequence, a bleeding tendency.

Others (eg, hydralazine) may modify host tissue and induce the production of autoantibodies directed at cell DNA. As a result, disease manifestations resembling those of systemic lupus erythematosus occur. In Goodpasture's syndrome, antibody to basement membranes of the kidneys and lungs bind to those membranes and activate complement.

Page 31: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

TYPE III: IMMUNE-COMPLEX HYPERSENSITIVITYTYPE III: IMMUNE-COMPLEX HYPERSENSITIVITY

occurs when antigen-antibody complexes induce an inflammatory response in tissues. Normally, immune complexes are promptly removed by the retticuloendothelial system, but occasionally they persist and are deposited in tissues, resulting in several disorders. In persistent microbial or viral infections, immune complexes may be deposited in organs, eg, the kidneys, resulting in damage. In autoimmune disorders, "self antigens may elicit antibodies that bind to organ antigens or deposit in organs as complexes, especially in joints (arthritis), kidneys (nephritis), or blood vessels (vasculitis).

Page 32: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 33: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Wherever immune complexes are deposited, they activate the complement system. Polymorphonuclear cells are attracted to the site, and inflammation and tissue injury occur.

Page 34: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Arthus Reaction is the name given to the inflammation caused by the deposition of immune complexes at a localized site. It is named for Arthus, who first described the inflammatory, response that occurs under the following conditions. If animals are given an antigen repeatedly until they have high levels of IgG antibody and that antigen is then injected subcutaneously or intradermally, intense edema and hemorrhage develop, reaching a peak in 3-6 hours. Antigen, antibody, and complement are deposited in vessel walls; polymorphonuclear cell infiltration inlravascular clumping or platelets then occur. These reactions can lead to vascular occlusion and necrosis. A clinical manifestation of the Arthus reaction is hypersensitivity pneumonitis (allergic alveolitis) associated with the inhalation of thermophilic actinomycetes ("farmer's lung").

Two typical type III hypersensitivity reactions are the Arthus reaction serum sickness.

Page 35: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Serum Sickness. In contrast to the Arthus reaction, which is localized inflammation, serum sickness is a systemic inflammatory response to the presence of immune complexes deposited in many areas of the body. After the injection of foreign serum (or, more commonly these days, certain drugs), the antigen is excreted slowly. During this time, antibody production starts. The simultaneous presence of antigen and antibody leads to the formation of immune complexes, which may circulate or be deposited at various sites. Typical serum sickness results in fever, urticaria, arthralgia. lymphadenopathy, splenomegaly, and eosinophilia a few days to 2 weeks after injection of the foreign serum or drug.

Page 36: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Immune-Complex Diseases

A. Glotnerulonephritis: Acute poststreptococcal glomerulonephritis is a well-accepted immune-complex disease.

B. Rheumatoid Arthritis: Rheumatoid arthritis is a chronic inflammatory autoimmune disease of the joints seen commonly in young women.

C. Systemic Lupus Erythematosus: is a chronic inflammatory autoimmune disease that affects several organs, especially the skin of the face, the joints, and the kidneys.

Page 37: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

TYPE IV: DELAYED (CELL-TYPE IV: DELAYED (CELL-MEDIATED) HYPERSENSITIVITYMEDIATED) HYPERSENSITIVITY

is a function of T lymphocytes, not antibody. It can be transferred by immunologically committed (sensitized) T cells, not by serum. The response is "delayed"; ie, it starts hours (or days) after contact with the antigen and often lasts for days.In certain contact hypersensitivities, such as poison oak, the pruritic, vesicular skin rash is caused by CD-8-positive cytotoxic T cells that attack skin cells that display the plant oil as a foreign antigen. In the tuberculin skin test, the indurated skin rash is caused by CD-4-positive helper T cells and macrophages that are attracted to the injection site.

Page 38: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

TYPE IV: DELAYED (CELL-MEDIATED) TYPE IV: DELAYED (CELL-MEDIATED) HYPERSENSITIVITYHYPERSENSITIVITY

The sensitized lymphocytes carry on their surface receptors which are antideterminants, specific to the given antigen. They bind with the foreign antigen by means of these receptors and destroy it with their enzymes and by producing special humoral factors, lymphokinins, which act as auxiliary vehicles of cellular immunity. Some types of lymphokinins may mobilize non-immune lymphocytes and include them in the reactions of cellular immunity.

Page 39: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Contact Hypersensitivity: This manifestation of cell-mediated hyper- sensitivity occurs after sensitization with simple chemicals (eg, nickel, formaldehyde), plant materials (eg, poison ivy, poison oak), topically applied drugs (eg, sulfonamides, neomycin), some cosmetics, soaps, and other substances. In all cases, the small molecules acting as haptens enter the skin, attach to body proteins, and become complete antigens. Cell-mediated hypersensitivity is induced, particularly in the skin.

Page 40: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 41: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 42: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Upon a later skin contact with the offending agent, the sensitized per-

son develops erythema, itching, vesicles, eczema, or necrosis of skinwithin 12-48 hours.

Tuberculin-Type Hypersensitivity: Delayed hypersensitivity to antigens of microorganisms occurs in many infectious diseases and has been used as an aid in diagnosis. It is typified by the tuberculin reaction. When a patient previously exposed to Mycobacterium tuberculosis is injected with a small amount of tuberculin (PPD) intradermally, there is little reaction in the first few hours. Gradually, however, induration and redness develop and reach a peak in 48-72 hours. A positive skin test indicates that the person has been infected with the agent, but it does not confirm the presence of current disease. However, if the skin test converts from negative to positive, it suggests that the patient has been recently infected.

Cell-mediated hypersensitivity develops in many bacterial, viral, protozoan and helminthic infections.

A positive skin test response assists in diagnosis and provides support for chemoprophylaxis or chemotherapy.

Page 43: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Tuberculin (allergic) tests are used for detecting infection of children with M. tuberculosis and for determining infection with M. tuberculosis.

Skin test

Page 44: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 45: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

ALLERGY DIAGNOSTIC TESTS.

Many infectious diseases are associated with the development of the body's elevated sensitivity toward the causative agents and products of their metabolism. Allergy tests used for the diagnosis of bacterial, viral, and protozoal infections, as well as mycosis and helminthiasis, rely exactly on this phenomenon. Allergy tests are quite specific but not infrequently they can be observed in vaccinated individuals and in those with a history of the disease in question.

Page 46: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

All allergy tests are divided into two groups, namely, in vivo and in vitro tests.

The first group (in vivo) consists of cutaneous tests made directly on the patient and revealing allergy of immediate (in 20 min) or delayed (in 24-48 hrs) type.

Cutaneous Tests. Infective allergens are most often administered either intracutaneously or epidermally by rubbing them into scarified sites of the skin, less commonly they are injected subcutaneously.

Page 47: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

In Vitro Tests. These methods of investigation are safe for the patient, highly sensitive, and allow to carry out a quantitative assessment of the body's allergization. To date, a number of tests have become available in which reactions with T- and B-lymphocytes, tissue basophils, neutrophil granulocytes, etc. are employed for this purpose. These tests include inhibition of leucocyte migration and lymphocyte blast transformation, specific rosette formation, the parameter of neutrophil granulocyte damage, Shelley's basophil test, reaction of tissue basophil degranulation. Still another test involves determination of IgE in blood serum.

Page 48: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 49: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

An autograft (transfer of an individual's own tissue to another site in the body) is always permaently accepted, ie, it always "takes". A syngeneic graft is a transfer of tissue between genetically identical individuals, ie, identical twins, and almost always "takes" permanently. A xenograft, a transfer of tissue between-different species, is always rejected by an immunocom- petent recipient. An allograft is a graft between genetically different members of the same species, eg, from one human to another.

TRANSPLANTATIONTRANSPLANTATION

Page 50: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 51: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Allografls are usually rejected unless the recipient is given immunosuppressive drugs. The severity and rapidity of the rejection will vary depending on the degree of the differences be tween the donor and the recipient at the MHC loci.Allograft Rejection. Unless immunosuppressive measures are taken, allografts are rejected by a process called the allograft reaction. In an acute allograft reaction, vascularization of the graft is normal initially but in 11-14 days, marked reduction in circulation and mononuclear cell infiltration occurs, with eventual necrosis. This is called a primary ("first-set") reaction. A T cell-mediated reaction is the main cause of rejection of many types of grafts, eg, skin, but antibodies contribute to the rejection of certain transplants, especially bone marrow. In experimental animals, rejection of most types of grafts can be transferred by cells, not serum. Also, T cell-deficient animals do not re ject grafts but B cell-deficient animals do. If a second allograft from the same donor is applied to a sensitized recipient, it is rejected in 5-6 days. This accelerated ("second-set") reaction is caused primarily by presensitized cytotoxic T cells.

Page 52: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 53: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

The accepiance or rejection of a transplant is determined, in large part, by the class I and class II MHC proteins on the donor cells, with class II playing the major role. The proteins encoded by the DR locus are especially important. These alloantigens activate T cells, both helper and cytotoxic, which bear T cell receptors specific for the alloantigens.

The activated T cells proliferate and then react against the alloantigens on the donor cells. CD8-positive cytotoxic T cells do most of the killing of the allograft cells.

Page 54: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 55: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Graft-Versus-Host Reaction. Well-matched transplants of bone marrow may establish them selves initially in 85% of recipients, but subsequently a graft-versus-host (GVH) reaction develops in about two-thirds of them. There are three requirements for a GVH reaction to occur: (1) the graft must contain immunocompetent T cells; (2) the host must be immuno- compromised; and (3) the recipient must express antigens (eg, MHC proteins) foreign to the donor; ie, the donor T cells recognize the recipient cells as foreign. Among the main symptoms are maculopapular rash, jaundice, hepatosplenomegaly, and diarrhea. Many GVH reactions end in overwhelming infections and death.The GVH reaction can be reduced by treating the donor tissue with antithymocyte globulin or monoclonal antibodies before grafting; this eliminates mature T cells from the graft. Cyclosporine is also used to reduce the GVH reaction. It prevents the activation of T lymphocytes by inhibiting signal transduction within t cells.

Page 56: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 57: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY
Page 58: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Autoimmunity

In autoimmunity, our immune systems may fail to recognize our own body antigen as self and begin to produce antibodies against our own tissue antigens.

Some, such as myesthenia gravis, are due to the production of humoral antibodies.

Some, such as sympathetic ophthalmia, are due to delayed hypersensitivity reactions.

Page 59: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

Mechanisms of AutoimmunityA. Molecular Mimicry: Various bacteria and viruses are implicated as the source of cross-reacting antigens that trigger the activation of autoreactive T cells or B cells. For example, Reiter's syndrome occurs following Shigella or Chlamydia infections and Guillain-Barre syndrome occurs following Campylobacter infections. One of the best-characterized examples of molecular mimicry is the relationship between the M protein of Streptococcus pyogenes and the myosin of cardiac muscle. Antibodies against certain M proteins cross-react with cardiac myosin, leading to rheumatic fever.

Page 60: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

B. Alteration of Normal Proteins: Drugs can bind to normal proteins and make them immunogenic. Procainamide-induced systemic lupus erythematosus is an example of this mechanism.C. Release of Sequestered Antigens: Certain tissues, eg, sperm, central nervous system, and the lens of the eye, are sequestered so that their antigens are not exposed to the immune system. These are known as immunologically privileged sites. When such antigens enter the circulation accidentally, eg, after damage, they elicit both humoral and cellular responses; producing aspermatogenests, encephalitis, or endophthalmitis, respectively.

Page 61: HYPERSENSITIVITY. TRANSPLANTATION AND TUMOR IMMUNITY

D. Epitope Spreading: Epitope spreading is the term used to describe the new exposure of sequestered autoantigens as a result of damage to cells caused by viral infection. These newly exposed autoantigens stimulate autoreactive T cells and autoimmune disease results.